Halozyme Appoints Barbara Duncan to its Board of Directors

Halozyme Therapeutics (NASDAQ: HALO) announced the appointment of Barbara Duncan to its Board of Directors on February 6, 2023.

Rhea-AI Summary

Halozyme Therapeutics (NASDAQ: HALO) announced the appointment of Barbara Duncan to its Board of Directors on February 6, 2023. Ms. Duncan has over 25 years of experience in the biopharmaceutical industry, having served as CFO at Intercept Pharmaceuticals and held key positions at DOV Pharmaceutical and Lehman Brothers. Dr. Helen Torley, President and CEO, expressed confidence that Ms. Duncan’s financial expertise would contribute to the company's growth. Halozyme is known for its ENHANZE® technology, which improves drug delivery, having impacted over 600,000 patients globally.

Positive

• Barbara Duncan's extensive experience in biopharmaceuticals may enhance strategic decisions.
• Her financial expertise could potentially improve financial performance and investor confidence.

Negative

• Concerns about continuity and potential experience gaps from her previous roles.

Argus Session date unavailable

-1.54% session move Open Argus

Details

News Market Reaction – HALO

The recorded move for HALO in the trading session of this news was -1.54%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry.

"We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance experience to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Barbara's business leadership, financial expertise and board experience will add important insights and contributions to the continuing success and growth of the company."

Ms. Duncan most recently served as the Chief Financial Officer of Intercept Pharmaceuticals Inc., a biopharmaceutical company, from 2009 to 2016. Prior to Intercept, Ms. Duncan held senior leadership roles at DOV Pharmaceutical, Inc., a biotechnology company, including Chief Financial Officer and Chief Executive Officer. Prior to joining DOV, Ms. Duncan served as Vice President of Corporate Finance -Global Healthcare at Lehman Brothers Inc.

"It's an exciting opportunity to join Halozyme as a board member at this juncture of their success," said Barbara Duncan.  "With their disruptive drug delivery technologies and patient centric mission, I look forward to supporting Halozyme's continued growth and success."

Ms. Duncan holds a Master of Business Administration from the Wharton School, University of Pennsylvania and a Bachelor of Business Administration in Accounting from Louisiana State University.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE^® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 600,000 patient lives in post-marketing use in five commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE^® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED^®, TLANDO^® and NOCDURNA^® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceutical, Covis Pharma, Pfizer and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

Forward-Looking Statements

This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions and include statements in this press release related to Halozyme's intention to redeem all of the outstanding Notes. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com

Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-appoints-barbara-duncan-to-its-board-of-directors-301739070.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the significance of Barbara Duncan's appointment to Halozyme's board?

Barbara Duncan's appointment brings 25 years of biopharmaceutical experience, enhancing the board's expertise.

How might Barbara Duncan's experience impact Halozyme?

Her financial expertise may lead to improved financial strategies and growth opportunities.

When was Barbara Duncan appointed to Halozyme's Board of Directors?

Barbara Duncan was appointed on February 6, 2023.

What is Halozyme Therapeutics known for?

Halozyme is recognized for its ENHANZE® technology, improving drug delivery and patient experiences.

What previous roles did Barbara Duncan hold before joining Halozyme?

Barbara Duncan was the CFO of Intercept Pharmaceuticals and held senior positions at DOV Pharmaceutical and Lehman Brothers.